[DISCLOSURE]
Kang Stem Biotech (217730) announced on July 14 that Furestem-AD Injection has got approval from the Ministry of Food and Drug Safety to initiate phase 2b of its clinical trial.
Furestem-AD Injection is a cord blood-derived stem cell treatment for moderately subacute and chronic atopic dermatitis, the first of its kind to be developed in the world.
